The University of Saskatchewan’s Vaccine and Infectious Disease Organization (VIDO) will be working on new therapeutics, vaccines, and diagnostics to fight against infectious diseases of high concern, thanks to a new research contract from the National Institute of Allergy and Infectious Diseases (NIAID). The Indefinite Delivery/Indefinite Quantity contract will support VIDO’s work against infectious diseases and help increase VIDO’s global presence. “This award further demonstrates the impact VIDO has on the world and helps to ensure we are prepared for the next pandemic,” said VIDO Director Dr Volker Gerdts. VIDO was the only Canadian organization out of four awardees selected.
USask
